Member Info for Laura2022

By all accounts the TG group is a waste of time with 1 or 2 people who don't hold constantly stopping people posting information

£1.5mln cap

£600-700k cash ,no debt small losses

CE0 salary £72k is 1/4 of AIM average = modest and alligned

Record contracts won June 2023 to June 2024 £1mln

Record revenues going into end of H1 2024 of currently £800-900k (up to Dec 2024)

Only needs about £1.4mln FY revenues end of June 2025 to probably turn to profit

Working in niche A.I software development market worth $blns

New CEO made huge impact in just 9mths

Potentially very large bio statistic contracts to come (words of BOD at last presentation)

Access to EU and USA markets via NASDAQ partners

Morning Scdm

The bigger picture is far beyond 0.8/09

Great post from BasilAlderman

Yes, that £20 Million MCAP suggestion is peanuts. More like £200 Million for starters in our space, when you read the PWC's dealmaker report on our sector.. It makes for interesting reading. See below for a summary of why PYC is so under valued:

1. Dealmakers in pharmaceuticals and life sciences and in healthcare services are eager to get deals done.

2. Competition for truly innovative assets remains intense.

3. Large pharmaceutical companies will continue to pursue biotech targets and products that can offset revenue declines from lost exclusivity in the coming years.

4. Companies seeking opportunities to digitalise through implementation of analytics technology, digital direct-to-consumer therapeutics offerings, smart health devices and other software innovations will continue to acquire or partner with data and analytics and other technology companies that can deliver these digital solutions.

For example:

5. Merck: Acquired Harpoon Therapeutics for an estimated $680 million

6. Novartis: Acquired Calypso Biotech for $250 million

7. Aditxt: Acquired Evofem Biosciences for $100 million

8. There were 420 M&A deals in our sector globally in Q3 2024, worth a total value of $32.4bn. Source: GlobalData’s Deals Database.

9. The $3.2bn acquisition of Morphic Holdings by Eli Lilly and Co was the industry’s largest disclosed deal in Q3 2024.

10. Interestingly for PYC investors AI / State of the art virtual technology accounted for 11 pharmaceutical deals announced in Q3 2024, worth a total value of $1.7bn. The $1.1bn acquisition of Integrated Oncology Network by Cardinal Health was the industry’s largest disclosed deal.

https://www.pwc.com/gx/en/services/deals/trends/health-industries.html

First shipment

Morning debull

That's interesting regarding Numab

£1.5mln cap

£600-700k cash ,no debt small losses

CE0 salary £72k is 1/4 of AIM average = modest and alligned

Record contracts won June 2023 to June 2024 £1mln

Record revenues going into end of H1 2024 of currently £800-900k (up to Dec 2024)

Only needs about £1.4mln FY revenues end of June 2025 to probably turn to profit

Working in niche A.I software development market worth $blns

New CEO made huge impact in just 9mths

Potentially very large bio statistic contracts to come (words of BOD at last presentation)

Access to EU and USA markets via NASDAQ partners

Maybe show up tommrow ?

Welcome Humpa

As you saw with FAB ( 2p to7p) these proper , well run companies will get a proper re rate

Pyc has no debt, small losses, record contracts last year, a record start to this new financial year

As you suggest..PYC a whisker from profitability at this rate

10. Interestingly for PYC investors AI / State of the art virtual technology accounted for 11 pharmaceutical deals announced in Q3 2024, worth a total value of $1.7bn. The $1.1bn acquisition of Integrated Oncology Network by Cardinal Health was the industry’s largest disclosed deal.

https://www.pwc.com/gx/en/services/deals/trends/health-industries.html

Rns can come any time of the day

PYC has had intra day before

Thanks Basil

KingHomer

Please could you explain the A.I dosing app for new people if yoi could take the time

Thanks

This should be 10p

Yeah right

Please let us know which one BEFORE you do ( you went quiet last night)

This poster has some good information

KingHomerJ

Posted in: PYC

Posts: 1,662

Price: 0.65

No Opinion

RE: Contract Value5 Dec 2024 07:40

500k as per RNS on the 13th September

13th September £65k

17th September unknown Cancer Research UK

5th December £157k

Plus £197k Grant when the NHS Trial kicks off

£900k plus

Market Cap £1.2million

Predictive AI modelling companies can be valued at x30

There revenues ……

At 71/72 it looks like there trying to confuse people

Also this is now £1mln of contracts won since June 2024

With a potential for £6mln from VAL deal on 31st Dec (VAL201) and the massive potential of our tech being fully integrated into our NASDAQ JV partner DoseMeRx

Trench

By my rough calcs PYC will have got £1mln revenues for this J1

All for £1.lln cap

I'm expecting a "ahead of expectations " trading update at this rate

As you say £1.5mln cap should be x 10

Up now 50%+ in one month

TRLS PYC could be interesting

This latest collaboration builds on Physiomics' strong relationship with Numab Therapeutics AG and highlights its expertise in using modelling and simulation approaches to accelerate the development of innovative therapies across a range of therapeutic areas and across the entire drug development pathway, including early discovery and development.